Fmr LLC Sells 170 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Fmr LLC decreased its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 17.7% in the 3rd quarter, HoldingsChannel reports. The fund owned 792 shares of the company’s stock after selling 170 shares during the period. Fmr LLC’s holdings in Invesco Biotechnology & Genome ETF were worth $55,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PBE. Cetera Investment Advisers boosted its stake in Invesco Biotechnology & Genome ETF by 2.1% in the 2nd quarter. Cetera Investment Advisers now owns 27,893 shares of the company’s stock valued at $1,808,000 after buying an additional 561 shares in the last quarter. One Capital Management LLC increased its holdings in shares of Invesco Biotechnology & Genome ETF by 31.9% in the second quarter. One Capital Management LLC now owns 25,402 shares of the company’s stock valued at $1,646,000 after purchasing an additional 6,137 shares in the last quarter. Massachusetts Wealth Management raised its position in shares of Invesco Biotechnology & Genome ETF by 7.3% during the third quarter. Massachusetts Wealth Management now owns 18,184 shares of the company’s stock worth $1,270,000 after acquiring an additional 1,240 shares during the last quarter. Creative Financial Designs Inc. ADV raised its holdings in Invesco Biotechnology & Genome ETF by 5.6% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock worth $393,000 after purchasing an additional 299 shares during the last quarter. Finally, Carnegie Investment Counsel bought a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter worth approximately $204,000.

Invesco Biotechnology & Genome ETF Stock Down 0.1 %

NYSEARCA:PBE opened at $67.46 on Wednesday. Invesco Biotechnology & Genome ETF has a 12-month low of $59.32 and a 12-month high of $72.84. The firm has a market capitalization of $272.54 million, a P/E ratio of 17.12 and a beta of 0.88. The stock’s fifty day simple moving average is $69.14 and its 200-day simple moving average is $68.64.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.